SCHEMBL172113

SCHEMBL172113

CC(C)(C)C1CC(C(C)(C)C)C(O)C(C(C)(C)C)C1

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8863482 0.86
SCHEMBL19156749 0.85 SLC18A3 (0.35)
SCHEMBL22023850 0.85
SCHEMBL17643565 0.79
SCHEMBL18900942 0.79
SCHEMBL16349212 0.79
SCHEMBL30155 0.79 LMNA (0.32) GBA1
SCHEMBL14473283 0.79 CYP2C9 (0.32) GBA1
SCHEMBL13900980 0.79 CYP2C9 (0.32) GBA1
SCHEMBL14640205 0.79 LMNA (0.32) GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183571-A1 LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS MERCK PATENT GMBH (DE) 2023-06-15 US disclosed
US-20230183571-A1 LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS MERCK PATENT GMBH (DE) 2023-06-15 US disclosed
US-11667845-B2 Liquid crystalline medium MERCK PATENT GMBH (DE) 2023-06-06 US disclosed
US-11667845-B2 Liquid crystalline medium MERCK PATENT GMBH (DE) 2023-06-06 US disclosed
US-20170362506-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2017-12-21 US disclosed
US-20170362506-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2017-12-21 US disclosed
EP-3228681-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2017-10-11 EP disclosed
WO-2017162707-A1 CYANOPYRIMIDINE DERIVATIVES SUITABLE AS COMPONENTS IN LIQUID CRYSTAL MEDIA MERCK PATENT GMBH (DE) 2017-09-28 WO disclosed
WO-2017162717-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2017-09-28 WO disclosed
WO-2017162716-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2017-09-28 WO disclosed
WO-2007017008-A1 ELECTRO-OPTICAL LIGHT MODULATION ELEMENT, DISPLAY AND MEDIUM MERCK PATENT GMBH (DE) 2007-02-15 WO disclosed
WO-2007017180-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2007-02-15 WO disclosed
EP-1752510-A1 Liquid crystalline medium Merck Patent GmbH (DE) 2007-02-14 EP disclosed
EP-1431369-B1 Liquid crystalline medium MERCK PATENT GMBH (DE) 2007-01-31 EP disclosed
WO-2007009636-A1 S-INDACENE AND INDENO[5,6-D][1,3]DIOXOL-DERIVATIVES AND USE THEREOF AS COMPONENTS OF LIQUID-CRYSTAL MIXTURES MERCK PATENT GMBH (DE) 2007-01-25 WO disclosed
EP-1746079-A2 Fluorinated biphenyl compounds for use in liquid crystal compositions Merck Patent GmbH (DE) 2007-01-24 EP disclosed
US-20070001149-A1 Liquid-crystal medium containing monofluoroterphenyl compounds MERCK PATENT GMBH (DE) 2007-01-04 US disclosed
EP-1310474-B1 Fluorinated biphenyl compounds and their use in liquid crystal compositions MERCK PATENT GMBH (DE) 2007-01-03 EP disclosed
EP-1365001-B1 Liquid crystalline medium MERCK PATENT GMBH (DE) 2007-01-03 EP disclosed
EP-1561150-B1 ELECTROOPTICAL LIGHT MODULATING ELEMENT, ELECTROOPTICAL DISPLAY AND MODULATING MEDIUM MERCK PATENT GMBH (DE) 2007-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667845-B2 Liquid crystalline medium NEFM, CCNI, MYT1 GBA1 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.